SCHEMBL19686829

SCHEMBL19686829

CCOC(=O)c1ccn(-c2nc(NC3CCC(F)(F)CC3)cc(OC3CN(C(=O)OC(C)(C)C)C3)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 3/20 0.38
IDH2 P48735 1/20 0.38
HPGD P15428 3/20 0.38
TP53 P04637 2/20 0.38
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
IL1B P01584 1/20 0.34
P2RX7 Q99572 1/20 0.34
SYK P43405 1/20 0.33
CCNT1 O60563 1/20 0.33
ROCK2 O75116 1/20 0.33
POLB P06746 1/20 0.33
CACNB4 O00305 1/20 0.33
CACNA1A O00555 1/20 0.33
CACNA1G O43497 1/20 0.33
CACNG3 O60359 1/20 0.33
CACNA1F O60840 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31127152 1.00 IDH1 (0.38) IDH1IDH2HPGDTP53KDM4E
SCHEMBL21143732 0.95 IDH1 (0.40) IDH1IDH2HPGDTP53KDM4E
SCHEMBL31127074 0.90 IDH1 (0.41) IDH1IDH2ALDH1A1MAPTIL1B
SCHEMBL19687490 0.90 IDH1 (0.41) IDH1IDH2ALDH1A1MAPTIL1B
SCHEMBL21143685 0.89 IDH1 (0.37) IDH1IDH2HPGDTP53KDM4E
SCHEMBL31127298 0.88 IDH1 (0.40) IDH1IDH2ALDH1A1MAPTIL1B
SCHEMBL19686831 0.88 IDH1 (0.40) IDH1IDH2ALDH1A1MAPTIL1B
SCHEMBL19686556 0.87 IDH1 (0.39) IDH1IDH2ALDH1A1MAPTIL1B
SCHEMBL19687510 0.87 KDM4E (0.39) IDH1HPGDTP53KDM4EALDH1A1
SCHEMBL19687508 0.87 HSD17B10 (0.40) IDH1HPGDTP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885IDH2 2447/4885HPGD 1676/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885IDH2 2447/4885HPGD 1676/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885IDH2 2447/4885HPGD 1676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.